Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents with atezolizumab (Atezo) for patients with recurrent or persistent endometrial cancer (EC) (1303)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
